MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
LYON, France--(BUSINESS WIRE)--Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux.
Under the liquidity contract entered between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2025:
- 35,760 shares
- €31,444.35
- Number of executions on buy side on semester: 3,000
- Number of executions on sell side on semester: 2,581
- Traded volume on buy side on semester: 85,600 shares for €529,308.98
- Traded volume on sell side on semester: 77,516 shares for €494,038.74
As a reminder:
-
the following resources appeared on the last half year statement on 31 December 2024 in the liquidity account:
- 27,676 shares
- €66,252.16
- Number of executions on buy side on semester: 1,085
- Number of executions on sell side on semester: 1,030
- Traded volume on buy side on semester: 32,984 shares for €251,038.29
- Traded volume on sell side on semester: 32,237 shares for € 249,744.48
-
the following resources appeared on the liquidity account when the activity started:
- 0 shares
- €200,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy Side | Sell Side | ||||||
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
||
| Total | 3,000 |
85,600 |
529,308.98 |
|
2,581 |
77,516 |
494,038.74 |
| 01/02/2025 | 17 |
290 |
2,317.10 |
|
13 |
377 |
3,027.31 |
| 01/03/2025 | 2 |
12 |
95.76 |
|
3 |
81 |
648.81 |
| 01/06/2025 | 6 |
172 |
1,388.04 |
|
18 |
436 |
3,535.96 |
| 01/07/2025 | 2 |
75 |
608.25 |
|
4 |
92 |
747.96 |
| 01/08/2025 | 12 |
267 |
2,152.02 |
|
1 |
25 |
202.00 |
| 01/09/2025 | - |
- |
- |
|
74 |
2,905 |
26,755.05 |
| 01/10/2025 | 33 |
1,381 |
11,586.59 |
|
14 |
562 |
5,041.14 |
| 01/13/2025 | 28 |
1,015 |
8,160.60 |
|
29 |
1,034 |
8,385.74 |
| 01/14/2025 | 18 |
465 |
3,766.50 |
|
26 |
857 |
7,035.97 |
| 01/15/2025 | 27 |
1,010 |
8,170.90 |
|
14 |
506 |
4,103.66 |
| 01/16/2025 | 14 |
550 |
4,411.00 |
|
6 |
189 |
1,527.12 |
| 01/17/2025 | 9 |
350 |
2,810.50 |
|
4 |
94 |
764.22 |
| 01/20/2025 | 13 |
363 |
2,958.45 |
|
36 |
1,040 |
8,517.60 |
| 01/21/2025 | 19 |
569 |
4,739.77 |
|
18 |
505 |
4,226.85 |
| 01/22/2025 | 12 |
400 |
3,316.00 |
|
12 |
360 |
3,006.00 |
| 01/23/2025 | 23 |
603 |
4,938.57 |
|
11 |
465 |
3,831.60 |
| 01/24/2025 | 26 |
750 |
6,045.00 |
|
16 |
253 |
2,061.95 |
| 01/27/2025 | 20 |
597 |
4,805.85 |
|
19 |
451 |
3,657.61 |
| 01/28/2025 | 17 |
505 |
4,055.15 |
|
11 |
420 |
3,385.20 |
| 01/29/2025 | 28 |
713 |
5,732.52 |
|
19 |
525 |
4,273.50 |
| 01/30/2025 | 31 |
735 |
5,902.05 |
|
19 |
695 |
5,636.45 |
| 01/31/2025 | 62 |
2,252 |
17,182.76 |
|
58 |
2,017 |
15,732.60 |
| 02/03/2025 | 52 |
1,582 |
11,865.00 |
|
14 |
428 |
3,222.84 |
| 02/04/2025 | 19 |
716 |
5,291.24 |
|
30 |
850 |
6,341.00 |
| 02/05/2025 | 2 |
70 |
516.60 |
|
9 |
260 |
1,924.00 |
| 02/06/2025 | 8 |
270 |
2,000.70 |
|
23 |
791 |
5,916.68 |
| 02/07/2025 | 19 |
540 |
4,087.80 |
|
15 |
570 |
4,354.80 |
| 02/10/2025 | 28 |
845 |
6,236.10 |
|
5 |
140 |
1,034.60 |
| 02/11/2025 | 22 |
340 |
2,482.00 |
|
10 |
244 |
1,790.96 |
| 02/12/2025 | 27 |
780 |
5,740.80 |
|
26 |
766 |
5,683.72 |
| 02/13/2025 | 21 |
423 |
3,096.36 |
|
16 |
513 |
3,791.07 |
| 02/14/2025 | 25 |
812 |
5,911.36 |
|
13 |
410 |
3,005.30 |
| 02/17/2025 | 21 |
663 |
4,733.82 |
|
12 |
370 |
2,664.00 |
| 02/18/2025 | 7 |
140 |
995.40 |
|
21 |
609 |
4,360.44 |
| 02/19/2025 | 16 |
432 |
3,067.20 |
|
7 |
150 |
1,065.00 |
| 02/20/2025 | 37 |
1,280 |
8,704.00 |
|
33 |
925 |
6,336.25 |
| 02/21/2025 | 13 |
525 |
3,507.00 |
|
11 |
295 |
1,985.35 |
| 02/24/2025 | 13 |
334 |
2,241.14 |
|
13 |
373 |
2,514.02 |
| 02/25/2025 | 13 |
368 |
2,465.60 |
|
7 |
165 |
1,113.75 |
| 02/26/2025 | 12 |
284 |
1,894.28 |
|
11 |
350 |
2,348.50 |
| 02/27/2025 | 30 |
983 |
6,409.16 |
|
9 |
210 |
1,392.30 |
| 02/28/2025 | 20 |
547 |
3,495.33 |
|
20 |
403 |
2,591.29 |
| 03/03/2025 | 21 |
654 |
4,100.58 |
|
16 |
460 |
2,898.00 |
| 03/04/2025 | 55 |
1,381 |
8,493.15 |
|
19 |
371 |
2,344.72 |
| 03/05/2025 | 12 |
300 |
1,815.00 |
|
30 |
977 |
6,008.55 |
| 03/06/2025 | 30 |
790 |
4,850.60 |
|
3 |
130 |
798.20 |
| 03/07/2025 | 9 |
255 |
1,555.50 |
|
7 |
325 |
1,992.25 |
| 03/10/2025 | 7 |
250 |
1,507.50 |
|
- |
- |
- |
| 03/11/2025 | 41 |
1,282 |
7,486.88 |
|
9 |
317 |
1,895.66 |
| 03/12/2025 | 55 |
1,559 |
9,322.82 |
|
75 |
2,475 |
15,023.25 |
| 03/13/2025 | 38 |
843 |
4,897.83 |
|
13 |
419 |
2,442.77 |
| 03/14/2025 | 17 |
505 |
2,929.00 |
|
23 |
856 |
5,024.72 |
| 03/17/2025 | 12 |
405 |
2,442.15 |
|
18 |
448 |
2,714.88 |
| 03/18/2025 | 12 |
296 |
1,764.16 |
|
6 |
74 |
445.48 |
| 03/19/2025 | 33 |
890 |
5,678.20 |
|
76 |
1,890 |
12,152.70 |
| 03/20/2025 | 42 |
1,426 |
8,670.08 |
|
11 |
269 |
1,654.35 |
| 03/21/2025 | 33 |
896 |
5,205.76 |
|
7 |
255 |
1,501.95 |
| 03/24/2025 | 9 |
244 |
1,390.80 |
|
1 |
40 |
229.60 |
| 03/25/2025 | 4 |
95 |
555.75 |
|
31 |
1,010 |
5,898.40 |
| 03/26/2025 | 5 |
195 |
1,193.40 |
|
40 |
1,364 |
8,361.32 |
| 03/27/2025 | 35 |
1,112 |
7,027.84 |
|
40 |
1,233 |
8,088.48 |
| 03/28/2025 | 46 |
1,617 |
10,041.57 |
|
28 |
1,004 |
6,365.36 |
| 03/31/2025 | 51 |
1,393 |
8,330.14 |
|
45 |
1,686 |
10,234.02 |
| 04/01/2025 | 11 |
289 |
1,849.60 |
|
29 |
825 |
5,321.25 |
| 04/02/2025 | 30 |
879 |
5,493.75 |
|
54 |
1,837 |
11,958.87 |
| 04/03/2025 | 46 |
1,140 |
6,931.20 |
|
6 |
97 |
612.07 |
| 04/04/2025 | 38 |
1,365 |
7,930.65 |
|
25 |
719 |
4,421.85 |
| 04/07/2025 | 9 |
350 |
1,928.50 |
|
44 |
1,323 |
7,752.78 |
| 04/08/2025 | 13 |
405 |
2,579.85 |
|
38 |
1,140 |
7,330.20 |
| 04/09/2025 | 23 |
665 |
4,156.25 |
|
6 |
181 |
1,138.49 |
| 04/10/2025 | 20 |
645 |
3,973.20 |
|
19 |
504 |
3,190.32 |
| 04/11/2025 | 15 |
405 |
2,425.95 |
|
8 |
109 |
667.08 |
| 04/14/2025 | 10 |
204 |
1,207.68 |
|
11 |
345 |
2,059.65 |
| 04/15/2025 | 8 |
164 |
993.84 |
|
39 |
1,090 |
6,638.10 |
| 04/16/2025 | 32 |
978 |
5,926.68 |
|
29 |
1,086 |
6,689.76 |
| 04/17/2025 | 24 |
678 |
4,088.34 |
|
3 |
87 |
526.35 |
| 04/22/2025 | 15 |
496 |
2,921.44 |
|
6 |
195 |
1,152.45 |
| 04/23/2025 | 13 |
350 |
2,086.00 |
|
19 |
525 |
3,150.00 |
| 04/24/2025 | 14 |
446 |
2,604.64 |
|
6 |
213 |
1,250.31 |
| 04/25/2025 | 21 |
404 |
2,391.68 |
|
27 |
813 |
4,845.48 |
| 04/28/2025 | 36 |
833 |
4,923.03 |
|
26 |
750 |
4,492.50 |
| 04/29/2025 | 35 |
789 |
4,639.32 |
|
24 |
660 |
3,946.80 |
| 04/30/2025 | 33 |
898 |
5,217.38 |
|
19 |
501 |
2,970.93 |
| 05/02/2025 | 14 |
321 |
1,848.96 |
|
18 |
330 |
1,920.60 |
| 05/05/2025 | 35 |
1,074 |
6,143.28 |
|
11 |
245 |
1,408.75 |
| 05/06/2025 | 31 |
930 |
5,170.80 |
|
17 |
414 |
2,343.24 |
| 05/07/2025 | 13 |
446 |
2,435.16 |
|
12 |
400 |
2,204.00 |
| 05/08/2025 | 14 |
435 |
2,388.15 |
|
25 |
785 |
4,341.05 |
| 05/09/2025 | 18 |
610 |
3,367.20 |
|
11 |
253 |
1,419.33 |
| 05/12/2025 | 76 |
2,743 |
14,428.18 |
|
61 |
1,840 |
9,880.80 |
| 05/13/2025 | 49 |
1,329 |
6,897.51 |
|
34 |
1,026 |
5,417.28 |
| 05/14/2025 | 65 |
1,991 |
10,193.92 |
|
49 |
1,689 |
8,765.91 |
| 05/15/2025 | 17 |
474 |
2,407.92 |
|
15 |
365 |
1,868.80 |
| 05/16/2025 | 24 |
606 |
3,048.18 |
|
16 |
532 |
2,697.24 |
| 05/19/2025 | 31 |
684 |
3,392.64 |
|
20 |
563 |
2,809.37 |
| 05/20/2025 | 21 |
485 |
2,444.40 |
|
16 |
486 |
2,468.88 |
| 05/21/2025 | 13 |
431 |
2,146.38 |
|
24 |
551 |
2,766.02 |
| 05/22/2025 | 18 |
395 |
1,978.95 |
|
22 |
590 |
2,997.20 |
| 05/23/2025 | 56 |
1,383 |
6,859.68 |
|
37 |
961 |
4,805.00 |
| 05/26/2025 | 23 |
713 |
3,401.01 |
|
15 |
457 |
2,239.30 |
| 05/27/2025 | 32 |
885 |
4,363.05 |
|
31 |
884 |
4,420.00 |
| 05/28/2025 | 13 |
260 |
1,271.40 |
|
11 |
193 |
951.49 |
| 05/29/2025 | 12 |
328 |
1,613.76 |
|
17 |
544 |
2,692.80 |
| 05/30/2025 | 6 |
165 |
816.75 |
|
30 |
758 |
3,797.58 |
| 06/02/2025 | 25 |
753 |
3,697.23 |
|
10 |
255 |
1,318.35 |
| 06/03/2025 | 28 |
760 |
3,883.60 |
|
68 |
2,323 |
12,846.19 |
| 06/04/2025 | 103 |
2,830 |
15,366.90 |
|
16 |
407 |
2,271.06 |
| 06/05/2025 | 26 |
748 |
4,046.68 |
|
41 |
1,109 |
6,099.50 |
| 06/06/2025 | 39 |
1,057 |
5,707.80 |
|
25 |
771 |
4,217.37 |
| 06/09/2025 | 33 |
850 |
4,615.50 |
|
20 |
683 |
3,756.50 |
| 06/10/2025 | 32 |
954 |
4,998.96 |
|
15 |
390 |
2,059.20 |
| 06/11/2025 | 6 |
149 |
785.23 |
|
27 |
750 |
4,012.50 |
| 06/12/2025 | 20 |
434 |
2,308.88 |
|
14 |
409 |
2,224.96 |
| 06/13/2025 | 34 |
841 |
4,507.76 |
|
26 |
825 |
4,496.25 |
| 06/16/2025 | 18 |
611 |
3,274.96 |
|
21 |
697 |
3,742.89 |
| 06/17/2025 | 18 |
395 |
2,069.80 |
|
11 |
318 |
1,675.86 |
| 06/18/2025 | 27 |
467 |
2,447.08 |
|
13 |
304 |
1,611.20 |
| 06/19/2025 | 32 |
602 |
3,166.52 |
|
21 |
516 |
2,750.28 |
| 06/20/2025 | 23 |
500 |
2,635.00 |
|
11 |
320 |
1,699.20 |
| 06/23/2025 | 18 |
536 |
2,749.68 |
|
12 |
272 |
1,411.68 |
| 06/24/2025 | 27 |
606 |
3,072.42 |
|
14 |
404 |
2,072.52 |
| 06/25/2025 | 27 |
660 |
3,267.00 |
|
16 |
427 |
2,147.81 |
| 06/26/2025 | 11 |
203 |
1,012.97 |
|
14 |
335 |
1,681.70 |
| 06/27/2025 | 28 |
682 |
3,314.52 |
|
9 |
250 |
1,252.50 |
| 06/30/2025 | 7 |
495 |
2,351.25 |
|
19 |
571 |
2,746.51 |
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Contacts
MaaT Pharma – Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations
Pauline RICHAUD
Senior PR & Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Catalytic Agency – U.S. Media Relations
Heather Shea
Media relations for MaaT Pharma
+1 617-286-2013
heather.shea@catalyticagency.com
